Generate Biomedicines, Inc. (GENB) Análise de ações

Visão geral da empresa

Generate Biomedicines, Inc. operates within the biotechnology sector, specifically focusing on the field of generative biology to utilize machine learning for drug discovery and development. The company employs this technological approach to program novel protein therapeutics within the United States, utilizing protein-based modalities as its primary vehicle for advancing drug development initiatives. At a significant scale, the company maintains a market capitalization of $1.52B and employs a workforce of 312 individuals to support its operational activities. Its annual revenue for the trailing twelve months stands at $31.89M, figures that indicate a substantial valuation relative to its current top-line performance. This disparity between the market cap and the annual revenue suggests the market is pricing in significant future potential or asset value that is not yet reflected in current sales figures.

Saúde financeira

The company reported a revenue of $31.89M for the trailing twelve months, yet it recorded a net income of -$249,523,008 and an EBITDA of -$221,887,008 during the same period. The substantial gap between the positive revenue of $31.89M and the negative net income reveals a cost structure where operating expenses and research costs vastly exceed the gross revenue generated. Free cash flow stands at -$119,101,624, indicating that the company is currently consuming cash reserves to fund its operations and development pipeline rather than generating surplus liquidity. The gross margin is 0.0%, while the operating margin is -737.0% and the profit margin is 0.0%, metrics that collectively indicate the company is not yet profitable and is burning capital per unit of revenue. Although specific cash and debt figures are not disclosed in the available data, the current ratio is 2.85, which indicates a healthy short-term liquidity position with current assets significantly exceeding current liabilities. The return on equity is -81.7% and the return on assets is -34.6%, revealing that management has not yet generated positive returns on the capital invested by shareholders or the company's asset base.

Avaliação de valorização

The trailing P/E ratio is not available due to the lack of earnings, while the forward P/E is reported as -5.63, implying that the company is expected to remain unprofitable in the near term based on analyst projections. The price-to-book ratio is -0.98, a negative figure that indicates the market values the company at a level below its book value, often seen in capital-intensive biotechnology firms with intangible assets that are not fully captured on the balance sheet. The price-to-sales ratio is 47.71 and the EV/EBITDA is not available, suggesting that valuation is being driven primarily by revenue multiples rather than earnings multiples due to the absence of positive earnings. The stock has traded between a 52-week low of $11.00 and a 52-week high of $15.32, meaning the current trading price sits within a relatively narrow historical range with a beta that is not available to determine volatility relative to the broader market. The absence of a positive beta value limits the ability to assess systematic risk, but the price action suggests the stock is currently trading below its yearly peak.

Growth & Income

Revenue growth year-over-year and earnings growth year-over-year are not available in the provided data, preventing a direct comparison of whether earnings are growing faster or slower than revenue. The company does not pay a dividend, as indicated by a dividend yield of N/A and a payout ratio of 0.0%, which means the company reinvests all available earnings and cash flow back into research, development, and operational growth rather than distributing income to shareholders. This strategy of zero dividend payout is consistent with biotechnology companies in the development phase that prioritize funding their pipeline over returning capital to investors. Consequently, the overall growth and income profile is characterized by a focus on capital appreciation potential through product development rather than current income generation or dividend yields.